Ignite Creation Date:
2025-12-25 @ 12:44 AM
Ignite Modification Date:
2025-12-31 @ 1:31 PM
Study NCT ID:
NCT04285567
Status:
COMPLETED
Last Update Posted:
2025-10-08
First Post:
2020-02-25
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-05-28
Start Date Type:
ACTUAL
Primary Completion Date:
2024-03-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-03-19
Completion Date Type:
ACTUAL
First Submit Date:
2020-02-25
First Submit QC Date:
None
Study First Post Date:
2020-02-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-03-13
Results First Submit QC Date:
None
Results First Post Date:
2025-04-17
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-25
Last Update Post Date:
2025-10-08
Last Update Post Date Type:
ESTIMATED